Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

NCT05533697 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

361

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL: mRNA-4359
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab

Sponsor

ModernaTX, Inc.